Yap1 Mediates Trametinib Resistance in Head and Neck Squamous Cell Carcinomas
Sign Up to like & getrecommendations! Published in 2021 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-19-4179
Abstract: Purpose: In a head and neck squamous cell carcinoma (HNSCC) “window of opportunity” clinical trial, we reported that trametinib reduced MEK-Erk1/2 activation and resulted in tumor responses in a subset of patients. Here, we investigated… read more here.
Keywords: hsc3; yap1; resistance; trametinib ... See more keywords